View supplier listing 10% off with code IRONMAN

Peptide guide

CJC-1295 + Ipamorelin Peptide Guide & Supplier Listing Notes

Combination of GHRH analog and GH secretagogue

Combination GH secretagogue comparison

Blends and named protocols Educational guide Supplier transparency

Back to directory Compare supplier pages

Educational disclaimer

Informational reference only

This page is for educational and informational purposes only. PeptideSuppliers.org does not sell peptides, provide medical advice, or recommend human use.

Overview

CJC-1295 + Ipamorelin overview

CJC-1295 + Ipamorelin is a combination of a GHRH analog and a GH secretagogue. Published research most often places it within GH-axis stimulation and endocrine physiology.

The literature around CJC-1295 + Ipamorelin is usually interpreted through mechanism, study design, and compound identity. Closely related analogs, shorthand labels, and supplier naming conventions can make those distinctions especially important when comparing papers, trial records, and catalog listings.

Common supplier-market stack; educational comparison only. This broader context helps separate established findings from early-stage signals and keeps the compound anchored to the evidence base rather than to marketing language.

Research snapshot

Quick research reference

Research Category: Compound Protocol Research

Research Status: Common supplier-market stack; educational comparison only.

Common Areas Studied:

GH-axis stimulation and endocrine physiology

Related Compounds:

History

Where the compound came from and why researchers keep returning to it.

The history of CJC-1295 + Ipamorelin is easiest to understand as part of a broader research line rather than as a single isolated listing. Pairing GHRH analogs and ghrelin receptor agonists is common in supplier-market discussion because pathways differ.

That history is important because it shows what problem researchers were trying to solve, what earlier compounds shaped the field before CJC-1295 + Ipamorelin gained attention, and why the compound continues to be discussed in relation to later studies or newer analogs.

For GH secretagogues, that timeline runs through the original GHRP series in the 1980s and 90s, sermorelin's approval as a GHRH analog, and the later development of longer-acting variants like CJC-1295 that extend GHRH receptor activation beyond the short half-life of native GHRH.

Mechanism of Action

Receptors, pathways, and the biological logic that shapes the research conversation.

In this combination, CJC-1295 targets the GHRH receptor while Ipamorelin targets the ghrelin/GHSR pathway, so the two compounds are studied for conceptually complementary signaling rather than a single shared mechanism. This is the core biological reason CJC-1295 + Ipamorelin is discussed alongside compounds such as CJC-1295, Ipamorelin, Sermorelin, Tesamorelin, and Hexarelin individually.

For this combination, that means separately tracking how GHRH-receptor activation from CJC-1295 and ghrelin/GHSR-receptor activation from Ipamorelin each contribute to pulsatile GH release, since the two pathways converge on GH secretion through different upstream signaling.

Ipamorelin is often grouped with older, less selective GHRPs even though it's one of the more receptor-selective ghrelin mimetics studied, with comparatively less reported effect on cortisol or prolactin than earlier-generation secretagogues. That selectivity distinction matters when comparing it to compounds like hexarelin.

Early work on GHRH analogs and GH secretagogues focused mainly on whether combining the two pathways produced a larger GH pulse than either alone; more recent interest has shifted toward body-composition and recovery-adjacent research questions, which is where most current supplier-market discussion is concentrated.

Research Areas

The main research domains where this compound appears most often.

Research area

GH/IGF-1 axis

Endocrine studies in this category usually track growth-hormone signaling, IGF-1 response, pituitary pathways, or related hormone-axis dynamics.

Research area

Endocrine signaling

Endocrine studies in this category usually track growth-hormone signaling, IGF-1 response, pituitary pathways, or related hormone-axis dynamics.

Research area

Body-composition research models

Published work in this area varies by model, endpoint, and stage of development, so the most useful reading approach is to focus on the specific outcomes each study actually measures.

Research area

Pathway comparison

Published work in this area varies by model, endpoint, and stage of development, so the most useful reading approach is to focus on the specific outcomes each study actually measures.

Animal studies

What preclinical work has emphasized

Class-level endocrine studies exist for each individual compound in this pairing, though evidence specific to the combined stack is more limited. This part of the literature often sets the first expectations around mechanism, tissue effects, or metabolic signaling, but those early signals need to be read with the normal limits of preclinical work in mind.

Preclinical GH-axis work on this combination draws heavily on rodent and some primate GH-pulse studies, using dosing intervals that don't map cleanly onto the daily or twice-daily protocols discussed in supplier-market forums.

The clearest preclinical summaries specify whether a study measured acute GH pulse amplitude or downstream IGF-1 change over time, since those are different endpoints with different levels of supporting evidence for this pairing.

Human studies

How much human evidence exists

Human evidence for this exact combination remains limited compared with the individual compounds studied on their own. When human data do exist, the best summaries distinguish the type of study being discussed, the population under investigation, and the limits of what the results can show.

For this stack specifically, most available human data comes from the individual compounds studied separately rather than the combination as dosed in supplier-market use, so trial design questions matter even more than usual when reading claims about the pairing.

The presence of published human GH-axis data for CJC-1295 or Ipamorelin individually doesn't establish evidence for the specific combined-stack dosing patterns discussed in forums and supplier marketing, which is a distinction worth keeping explicit.

Current research status

Where the research stands now

Common supplier-market stack; educational comparison only. For CJC-1295 + Ipamorelin, the current research picture should be read as a snapshot rather than a final verdict, because publication timelines, trial readouts, and category language can shift quickly.

GH secretagogue combinations get discussed heavily in bodybuilding and longevity-adjacent forums, which creates a lot of commercial noise relative to the actual trial record for the combined stack. The individual-compound literature is more developed than the combination-specific literature.

PubMed searches for CJC-1295 and Ipamorelin individually turn up more results than searches for the combination, which is a useful signal of how much of the literature actually tested the pairing as such.

Browse suppliers Open peptide directory Read education guides Best peptide suppliers

Related Compounds

Closely related compounds frequently discussed within the same research category.

CJC-1295 Ipamorelin Sermorelin Tesamorelin Hexarelin

Supplier considerations

How to read supplier pages more carefully

Avoid stack/protocol recommendations; evaluate documentation for each compound separately. In this context, the main issue is documentation quality rather than promotional language.

For CJC-1295 + Ipamorelin, documentation quality starts with naming discipline. If a listing uses shorthand, category labels, or adjacent compound references, the exact compound identity should still be easy to follow. COAs, third-party testing notes, and batch references should reinforce that naming rather than complicate it.

GHRH analogs and ghrelin-receptor peptides are typically supplied as lyophilized powder requiring refrigerated or frozen storage before reconstitution, and for a two-compound stack, that storage guidance should be clear for both components rather than only one.

Look for batch-specific COAs instead of generic laboratory files reused across many listings.
Check whether the product name, concentration language, and batch references stay consistent from page to page.
Read storage and handling notes alongside the document links rather than treating the headline purity claim as enough.
Prefer supplier pages that keep research-use labeling, contact details, and policy pages easy to verify.

Cross-reference

Related directory and education pages

Supplier reviews, directory entries, and education guides provide additional context for comparing documentation standards, related compounds, and broader category coverage.

Browse suppliers Open peptide directory Read education guides Best peptide suppliers

Linked supplier pages

Supplier pages that help compare naming, documentation access, batch references, and overall page clarity.

Supplier listing

Iron Peptides

This listing helps with checking naming, documentation access, storage language, and overall page clarity.

View supplier listing

10% off with code IRONMAN

Frequently Asked Questions

Common research questions about the compound, evidence base, and supplier documentation.

Why combine CJC-1295 and ipamorelin?

Common supplier-market stack; educational comparison only. The clearest interpretation comes from reading mechanism, evidence level, and supplier documentation together rather than relying on one isolated claim.

What does each target?

In this combination, CJC-1295 targets the GHRH receptor while Ipamorelin targets the ghrelin/GHSR pathway, offering conceptually complementary signaling rather than a single shared mechanism. That pathway-level description captures the main biological rationale being studied.

Is combo approved?

Common supplier-market stack; educational comparison only. Any approved-drug context or investigational status should stay explicit so the research record is not confused with a prescription pathway.

Difference between GHRH analog and GHRP?

Compare COAs separately?

Yes. Because this is a two-compound stack, look for separate batch-specific COAs covering both the CJC-1295 portion and the Ipamorelin portion rather than a single combined document.

What is CJC-1295 + Ipamorelin?

CJC-1295 + Ipamorelin is a combination of a GHRH analog and a GH secretagogue. Research literature on this compound is usually interpreted through mechanism, evidence level, and documentation quality.

What research areas is CJC-1295 + Ipamorelin usually linked to?

The main areas linked to CJC-1295 + Ipamorelin in this literature are the GH/IGF-1 axis, endocrine signaling, body-composition research models, and pathway comparison. Those categories reflect the published research record around the compound.

What should be verified on a CJC-1295 + Ipamorelin supplier page?

Avoid stack/protocol recommendations; evaluate documentation for each compound separately. In practice, that means checking batch-specific COAs, identity/purity language, research-use labeling, and overall page consistency.

How developed is the current CJC-1295 + Ipamorelin research literature?

Common supplier-market stack; educational comparison only. Trial records and literature searches are still the best way to verify where the field stands at any given point.

What makes CJC-1295 + Ipamorelin different from related compounds?

CJC-1295 + Ipamorelin is most usefully compared through mechanism and category fit. Nearby entries such as CJC-1295, Ipamorelin, Sermorelin, Tesamorelin help show how receptor logic, research emphasis, and documentation patterns differ without treating all of them as interchangeable.

References

Research entry points and source pages for verifying the broader literature.